|
LOBBYING REPORT |
Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required to Complete This Page
2. Address
| Address1 | Grand Central Station, PO Box 4777 |
Address2 |
|
| City | New York |
State | NY |
Zip Code | 10163 |
Country | USA |
3. Principal place of business (if different than line 2)
| City |
|
State |
|
Zip Code |
|
Country |
|
|
5. Senate ID# 401104060-12
|
||||||||
|
6. House ID# 432920001
|
||||||||
| TYPE OF REPORT | 8. Year | 2026 |
Q1 (1/1 - 3/31) | Q2 (4/1 - 6/30) | Q3 (7/1 - 9/30) | Q4 (10/1 - 12/31) |
9. Check if this filing amends a previously filed version of this report
| 10. Check if this is a Termination Report | Termination Date |
|
11. No Lobbying Issue Activity |
| INCOME OR EXPENSES - YOU MUST complete either Line 12 or Line 13 | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| 12. Lobbying | 13. Organizations | ||||||||
| INCOME relating to lobbying activities for this reporting period was: | EXPENSE relating to lobbying activities for this reporting period were: | ||||||||
|
|
||||||||
|
|
||||||||
| Provide a good faith estimate, rounded to the nearest $10,000, of all lobbying related income for the client (including all payments to the registrant by any other entity for lobbying activities on behalf of the client). | 14. REPORTING Check box to indicate expense accounting method. See instructions for description of options. | ||||||||
|
Method A.
Reporting amounts using LDA definitions only
Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code Method C. Reporting amounts under section 162(e) of the Internal Revenue Code |
|||||||||
| Signature | Digitally Signed By: Michael DeRose |
Date | 4/16/2026 12:48:57 PM |
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code HCR
16. Specific lobbying issues
General Parkinsons disease information, including disease burden, symptoms, health coverage, health care costs, environmental risk factors, and access to care for underserved communities.
Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy related to the development and execution of the National Parkinsons Project (NPP), interagency coordination, advisory council establishment, reporting requirements, and congressional oversight, as well as appropriations to support implementation activities.
Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)) and support for related congressional appropriations requests and communications.
National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy in appropriations to re-establish and expand Udall Centers, related report language, and coordination with the National Parkinsons Project.
Advanced Research Projects Agency for Health (ARPA-H) and neurodegenerative disease research, including advocacy for report language directing prioritization of high-risk, high-reward research on Parkinsons disease and related neurodegenerative conditions.
Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research, including advocacy for report language to expand funding eligibility to Parkinsons disease and related dementias and support research on the intersection of Parkinsons disease and dementia.
Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support data collection and surveillance of Parkinsons disease and related conditions.
Department of Health and Human Services (HHS) coordination on environmental risk factors and neurodegenerative disease prevention, including advocacy for report language and funding to support interagency coordination and research on toxic exposures and Parkinsons disease and related conditions.
The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for cosponsorship and provisions supporting research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.
Environmental risk factors and Parkinsons disease, including advocacy related to pesticide exposure and paraquat, and support for Environmental Protection Agency (EPA) action to reassess and restrict or ban paraquat due to links to Parkinsons disease.
The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to early detection of Alzheimers disease and related dementias and access to diagnostic tools.
The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care.
The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Natl Institutes of Health (NIH), Health & Human Services - Dept of (HHS), Defense - Dept of (DOD), Environmental Protection Agency (EPA), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
|
Sallie |
Weart |
|
|
|
Danielle |
Mutone-Smith |
|
USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director |
|
Grant |
Cope |
|
Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code MMM
16. Specific lobbying issues
Medicare and Medicaid coverage, access, and affordability of treatments for Parkinsons disease and other chronic conditions, including beneficiary access to care, prescription drug coverage, and utilization management policies.
The Alleviating Barriers for Caregivers (ABC) Act (H.R. 2491 / S. 1227), including advocacy related to simplifying Medicare and Social Security processes and improving access to benefits for caregivers and individuals with chronic conditions.
The Essential Caregivers Act of 2025 (H.R. 6766 / S. 3492), including advocacy related to ensuring access for designated essential caregivers in health care facilities during periods of restricted visitation under Medicare and Medicaid.
The Alzheimers Screening and Prevention (ASAP) Act (H.R. 6130 / S. 3267), including advocacy related to Medicare coverage of blood-based biomarker tests for early detection of Alzheimers disease and related dementias.
Centers for Medicare & Medicaid Services (CMS) policies, including advocacy related to Medicare Part D and Medicare Advantage, prescription drug affordability, formulary design, utilization management, beneficiary protections, and the CY 2027 Advance Notice.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
|
Danielle |
Mutone-Smith |
|
USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code BUD
16. Specific lobbying issues
Federal funding for Parkinsons disease and neurodegenerative disease research, care, and public health programs in Fiscal Year (FY) 2026 and FY 2027 appropriations legislation, including advocacy related to funding levels, report language, and congressional appropriations requests. Support overall funding increases for medical research and neurological condition research across NIH, ARPA-A, DOD, and VA.
Implementation of the Dr. Emmanuel Bilirakis and Honorable Jennifer Wexton National Plan to End Parkinsons Act (Public Law No. 118-66), including advocacy for appropriations to support implementation of the National Parkinsons Project (NPP), advisory council activities, and related reporting requirements consistent with enacted appropriations language.
Federal funding for Parkinsons disease and neurodegenerative disease research at the National Institutes of Health (NIH), including advocacy for increased appropriations for Parkinsons disease and related conditions across NIH institutes (including the National Institute of Neurological Disorders and Stroke (NINDS) and National Institute on Aging (NIA)), and increasing investment for neurological disease research such as the BRAIN Initiative.
National Institute of Neurological Disorders and Stroke (NINDS) Morris K. Udall Centers of Excellence for Parkinsons Disease Research, including advocacy for appropriations and related report language to expand the Udall Centers.
Advanced Research Projects Agency for Health (ARPA-H), including advocacy for report language directing prioritization of neurodegenerative disease research and alignment with emerging opportunities in chronic disease and aging research.
Department of Health and Human Services (HHS) environmental risk and prevention efforts, including advocacy for report language and appropriations to support interagency coordination and research on toxic exposures and neurodegenerative disease prevention.
Alzheimers Disease and Alzheimers Disease-Related Dementias (AD/ADRD) research funding, including advocacy for report language to expand eligibility to Parkinsons disease and related dementias.
Centers for Disease Control and Prevention (CDC) National Neurological Conditions Surveillance System (NNCSS), including advocacy for continued appropriations to support surveillance and data collection on Parkinsons disease and related conditions.
Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program (TERP) to support research on Parkinsons disease and service-related exposures.
Department of Veterans Affairs (VA) Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Neurology Centers of Excellence, including advocacy for increased appropriations and report language to support research, clinical care, and access for veterans living with Parkinsons disease.
Department of Veterans Affairs (VA) Office of Research and Development (ORD), including advocacy for report language to increase focus on Parkinsons disease and related conditions within VAs medical research portfolio.
Food and Drug Administration (FDA) National Center for Toxicological Research (NCTR), including advocacy for appropriations and report language supporting research on toxic exposures and Parkinsons disease.
Food and Drug Administration (FDA) neurodegenerative disease guidance and reporting, including advocacy for report language to improve coordination, transparency, and disease-specific guidance for Parkinsons disease and related conditions.
Food and Drug Administration (FDA) Neurology Drug Program to coordinate efforts on central nervous system drug development.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Disease Control & Prevention (CDC), Defense - Dept of (DOD), Food & Drug Administration (FDA), Health & Human Services - Dept of (HHS), Natl Institutes of Health (NIH), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sallie |
Weart |
|
|
|
Drew |
Hatter |
|
|
|
Mason |
Zeagler |
|
|
|
Danielle |
Mutone-Smith |
|
USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director |
|
Grant |
Cope |
|
Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code PHA
16. Specific lobbying issues
Prescription drug affordability and access for individuals with Parkinsons disease and other chronic conditions, including advocacy related to patient access to medications, cost-sharing, and barriers to accessing clinically appropriate medications.
Prescription drug coverage and access under Medicare, including advocacy related to policies impacting access to Parkinsons disease treatments, formulary placement, and utilization management.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Centers For Medicare and Medicaid Services (CMS), Health & Human Services - Dept of (HHS)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Danielle |
Mutone-Smith |
|
USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code VET
16. Specific lobbying issues
Medical research, clinical care, and access to services for veterans living with Parkinsons disease and other neurological conditions, including advocacy related to programs, research, and exposure-related risk factors within the Department of Veterans Affairs (VA) and Department of Defense (DOD).
Parkinsons Disease Research, Education and Clinical Centers (PADRECCs) and Department of Veterans Affairs (VA) Neurology Centers of Excellence, including advocacy for appropriations and report language to support specialized care, research, and access to services for veterans living with Parkinsons disease.
Department of Defense (DOD) Congressionally Directed Medical Research Programs (CDMRP), including advocacy for funding for the Parkinsons Research Program (PRP) and the Toxic Exposure Research Program to support research on Parkinsons disease and service-related exposures.
Research on service-related exposures and Parkinsons disease, including advocacy related to toxic exposures, traumatic brain injury, and other risk factors associated with military service and increased risk of neurodegenerative disease.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Defense - Dept of (DOD), Veterans Affairs - Dept of (VA)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Sallie |
Weart |
|
|
|
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
|
Danielle |
Mutone-Smith |
|
USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director |
|
Grant |
Cope |
|
Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code ENV
16. Specific lobbying issues
Environmental exposures and toxic substances linked to Parkinsons disease, including advocacy related to reducing or eliminating exposure to chemicals such as paraquat and other environmental contaminants associated with increased risk of neurodegenerative disease.
The Harmonizing Environmental Analyses and Launching Therapeutic Hubs to Yield Bolstered Research And Innovation in Neurological Science (HEALTHY BRAINS) Act (H.R. 7779), including advocacy for research on environmental risk factors and toxic exposures linked to neurodegenerative diseases.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE, Environmental Protection Agency (EPA), Natl Institutes of Health (NIH)
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Mason |
Zeagler |
|
|
|
Drew |
Hatter |
|
|
|
Grant |
Cope |
|
Senate Environment and Public Works Committee - Senior Counselor, EPA - Senior Counselor to the Administrator |
|
Sallie |
Weart |
|
|
|
Danielle |
Mutone-Smith |
|
USAID - Senior Policy and Program Officer, USAID - Policy Team Leader, USAID - Division Chief for Policy, Partnerships, Programs & Communications, USAID - Senior Policy Advisor, USAID - Managing Director |
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
LOBBYING ACTIVITY. Select as many codes as necessary to reflect the general issue areas in which the registrant engaged in lobbying on behalf of the client during the reporting period. Using a separate page for each code, provide information as requested. Add additional page(s) as needed.
15. General issue area code TAX
16. Specific lobbying issues
Tax policy related to financial support for family caregivers and individuals with chronic conditions, including advocacy to reduce out-of-pocket costs and improve affordability of care.
The Lowering Costs for Caregivers Act (S. 1565 / H.R. 138), including advocacy related to expanding the use of tax-advantaged health accounts (including HSAs, FSAs, and HRAs) to cover medical expenses for family caregivers and improving affordability of care.
The Credit for Caring Act of 2025 (S. 925 / H.R. 2036), including advocacy related to providing a nonrefundable tax credit to offset caregiving expenses for working family caregivers.
17. House(s) of Congress and Federal agencies Check if None
U.S. HOUSE OF REPRESENTATIVES, U.S. SENATE
18. Name of each individual who acted as a lobbyist in this issue area
| First Name | Last Name | Suffix | Covered Official Position (if applicable) | New |
Drew |
Hatter |
|
|
19. Interest of each foreign entity in the specific issues listed on line 16 above Check if None
Information Update Page - Complete ONLY where registration information has changed.
20. Client new address
| Address |
|
||||||
| City |
|
State |
|
Zip Code |
|
Country |
|
21. Client new principal place of business (if different than line 20)
| City |
|
State |
|
Zip Code |
|
Country |
|
22. New General description of client’s business or activities
LOBBYIST UPDATE
23. Name of each previously reported individual who is no longer expected to act as a lobbyist for the client
|
|
||||||||
| 1 |
|
3 |
|
||||||
| 2 |
|
4 |
|
ISSUE UPDATE
24. General lobbying issue that no longer pertains
|
|
|
|
|
|
|
|
|
AFFILIATED ORGANIZATIONS
25. Add the following affiliated organization(s)
Internet Address:
| Name | Address |
Principal Place of Business (city and state or country) |
||||||||||||
| ||||||||||||||
|
||||||||||||||
26. Name of each previously reported organization that is no longer affiliated with the registrant or client
| 1 | 2 | 3 |
FOREIGN ENTITIES
27. Add the following foreign entities:
| Name | Address |
Principal place of business (city and state or country) |
Amount of contribution for lobbying activities | Ownership percentage in client | ||||||||||
| ||||||||||||||
|
% | |||||||||||||
28. Name of each previously reported foreign entity that no longer owns, or controls, or is affiliated with the registrant, client or affiliated organization
| 1 | 3 | 5 |
| 2 | 4 | 6 |
CONVICTIONS DISCLOSURE
29. Have any of the lobbyists listed on this report been convicted in a Federal or State Court of an offense involving bribery,
extortion, embezzlement, an illegal kickback, tax evasion, fraud, a conflict of interest, making a false statement, perjury, or money laundering?
| Lobbyist Name | Description of Offense(s) |